Skip to main content

Table 1 Patients’ clinical and histopathological characteristics (n = 68)

From: CD146 as an adverse prognostic factor in uterine sarcoma

Characteristics No. case LMS (n = 36) ESS (n = 25) MMMT (n = 7)
Age (years)
 <50 38 (55.8 %) 20 17 1
 ≥50 30 (44.2 %) 16 8 6
Stage
 I 36 (53.9 %) 19 13 4
 II 3 (4.4 %) 3 0 0
 III 22 (32.4 %) 7 12 3
 IV 7 (10.3 %) 7 0 0
Tumor size (cm)
 <5 30 (44.1 %) 16 11 3
 ≥5 38 (55.9 %) 20 14 4
Pelvic lymphadenectomy
 Yes 34 (50 %) 17 13 4
 No 34 (50 %) 19 12 3
Lymph node metastasis
 Positive 24 (35.3 %) 18 4 2
 Negative 44 (64.7 %) 33 9 2
Surgical procedure
 TAH ± BSO/OT/PL/PLND 8 (11.8 %) 4 4 0
 TAH + BSO ±/PL/OT 29 (42.6 %) 17 12 0
 TAH + BSO + PL ± OT ± PLND 31 (45.6 %) 15 9 7
 Chemotherapy 22 (32.4 %) 13 9 0
 Radiotherapy 4 (5.9 %) 1 3 0
 Hormone therapy 1 (1.5 %) 0 1 0
 Chemotherapy and radiotherapy 20 (29.4 %) 10 3 7
 Chemotherapy and hormone therapy 3 (4.4 %) 1 2 0
 Radiotherapy and hormone therapy 1 (1.5 %) 0 1 0
 No adjuvant therapy 17 (25 %) 11 6 0
Distant metastasis and recurrence
 Pelvic 10 (14.7 %) 6 3 1
 Pelvic and liver/lung 6 (8.8 %) 4 2 0
 Lung 4 (5.9 %) 3 1 0
 Other parts 6 (8.8 %) 5 1 0
 None 42 (61.5 %) 18 18 6
  1. TAH total abdominal hysterectomy, BSO bilateral salpingo-oophorectomy, OT omentectomy, PL pelvic lymphadenectomy, PLND para-aortic lymph node dissection